论文部分内容阅读
目的:观察卡介菌多糖核酸(BCG-PSN)对常年性变应性鼻炎患者的免疫调节作用及临床疗效。方法:将60例常年性变应性鼻炎患者随机分为试验组和对照组,每组30例。试验组在与对照组相同治疗的基础上给予卡介菌多糖核酸注射液1ml(0.5mg),肌肉注射,隔日1次,疗程为6周。两组均随访3个月,每2周门诊随访1次,对临床情况进行评价,并检测两组患者治疗前、后血清IgA、IgG、IgM、IgE、CD3、CD4及CD8水平。结果:试验组有效率为93.33%,对照组为63.33%,其差异有统计学意义(P<0.05);卡介菌多糖核酸治疗后CD3、CD4、CD4/CD8水平均明显升高,分别与治疗前及对照组的治疗后比较,差异有统计学意义(均P<0.05)。治疗后IgA、IgM和IgE明显降低,与治疗前比较,差异均有统计学意义(均P<0.05),其中IgE与对照组的治疗后比较,差异亦有统计学意义(P<0.05)。结论:卡介菌多糖核酸可调节常年性变应性鼻炎患者的免疫功能,与抗过敏药物联合应用可提高其疗效,具有临床实用价值。
Objective: To observe the immunomodulatory effect and clinical efficacy of BCG polysaccharide nucleic acid (BCG-PSN) on patients with perennial allergic rhinitis. Methods: 60 cases of perennial allergic rhinitis were randomly divided into experimental group and control group, 30 cases in each group. The experimental group was treated with BCG polysaccharide nucleic acid injection 1ml (0.5mg) on the basis of the same treatment as the control group, intramuscularly and once every other day for 6 weeks. The patients in both groups were followed up for 3 months and were followed up every 2 weeks. The clinical conditions were evaluated and the levels of serum IgA, IgG, IgM, IgE, CD3, CD4 and CD8 were detected before and after treatment in both groups. Results: The effective rate of the experimental group was 93.33% and that of the control group was 63.33%, the difference was statistically significant (P <0.05); the levels of CD3, CD4 and CD4 / CD8 of the BCG-PSN group were significantly increased Before treatment and control group after treatment, the difference was statistically significant (P <0.05). IgA, IgM and IgE were significantly lower after treatment than before treatment, the difference was statistically significant (P <0.05), IgE and control group after treatment, the difference was also statistically significant (P <0.05). Conclusion: BCG-PSN can regulate the immune function of patients with perennial allergic rhinitis, and its combination with anti-allergy drugs can improve its curative effect and has clinical value.